Atherosclerotic renovascular disease and renal impairment: can we predict the effect of intervention?
Atherosclerotic renal artery stenosis (ARAS) is associated with hypertension, ischemic nephropathy, and high cardiovascular risk. We review the data on revascularization of the renal artery by percutaneous transluminal renal angioplasty (PTRA) and pharmacological therapy. In patients with severe ARAS and poorly controlled hypertension, PTRA can improve blood pressure control. In patients with rapid renal function loss and severe ARAS, PTRA can improve short-term renal function, but there is no evidence for long-term renoprotection. Recent evidence indicates that ARAS, and incidental renal artery stenosis, considerably increases cardiovascular risk, independent of blood pressure, renal function, and prevalent risk factors. This suggests that revascularization might potentially improve overall prognosis, but no data are available currently. The high cardiovascular risk warrants aggressive pharmacological treatment to prevent progression of the generalized vascular disorder. Ongoing trials will show whether revascularization has added, long-term effects on blood pressure, renal function, and cardiovascular prognosis.
Mui
Kwok-Wai
KW
Division of Nephrology, Department of Medicine, University Medical Center Groningen, Groningen, The Netherlands.
Woittiez
Arend-Jan
AJ
Navis
Gerjan
G
D050197:Atherosclerosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D006978:Hypertension, Renovascular / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D011237:Predictive Value of Tests; D012078:Renal Artery Obstruction / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D051437:Renal Insufficiency / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*